DiogenX is developing therapies that regenerate insulin-producing beta cells to offer disease‑modifying treatment for type 1 diabetes. Its lead program targets the Wnt/β-catenin signalling pathway to stimulate pancreatic beta‑cell regeneration. The lead candidate is currently in preclinical development. The company raised €27.5M in a Series A to advance that program toward clinical development in patients with T1D. The financing attracted strategic and diabetes-focused backers including Roche Venture Fund, Eli Lilly, Omnes, Boehringer Ingelheim Venture Fund, JDRF T1D Fund and Adbio Partners. DiogenX is led by CEO Benjamin Charles, was co‑founded by Patrick Collombat, Jean‑Pascal Tranié and Benjamin Charles, and is based in Marseille with research labs in Nice; David Evans joined the board as part of the financing. DiogenX is a preclinical-stage biotech developing pancreatic beta‑cell modulators intended to regenerate insulin-producing cells for patients with diabetes. The company’s candidate discovery originated in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University). DiogenX was founded in December 2019 and is led by CEO Benjamin Charles, with research labs in Nice and headquarters in Marseille, France. The company focuses on discovering a molecule that could offer beta‑cell regeneration therapy to improve quality of life and survival for T1D and T2D patients. It closed a seed financing round of €4.5m to advance its program. DiogenX plans to use the proceeds to select a drug candidate and prepare preclinical development ahead of a targeted Series A in late 2021.

Total raised

$35M

Funding rounds

2

Latest round

Series A

Latest activity

May 2023